Zirgan

Zirgan is a brand name of ganciclovir ophthalmic, approved by the FDA in the following formulation(s):

ZIRGAN (ganciclovir - gel; ophthalmic)

• 
  Manufacturer: BAUSCH AND LOMB
  
  Approval date: September 15, 2009
  
  Strength(s): 0.15% ^[RLD]

Has a generic version of Zirgan been approved?

No. There is currently no therapeutically equivalent version of Zirgan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zirgan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zirgan.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 15, 2012 - NEW DOSAGE FORM
  
  
  • September 15, 2016 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Zirgan Consumer Information (Drugs.com)
• Zirgan Gel Consumer Information (Wolters Kluwer)
• Zirgan Consumer Information (Cerner Multum)
• Zirgan Advanced Consumer Information (Micromedex)
• Ganciclovir Gel Consumer Information (Wolters Kluwer)
• Ganciclovir Implant Consumer Information (Wolters Kluwer)
• Ganciclovir ophthalmic Consumer Information (Cerner Multum)
• Ganciclovir Intraocular Advanced Consumer Information (Micromedex)
• Ganciclovir Ophthalmic Advanced Consumer Information (Micromedex)